Detalles de la búsqueda
1.
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
Blood
; 130(3): 310-322, 2017 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-28202458
2.
Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors.
Bioorg Med Chem Lett
; 27(13): 3030-3035, 2017 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28526367
3.
Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.
Cell Mol Life Sci
; 73(4): 883-900, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26346493
4.
Design of selective PI3Kα inhibitors starting from a promiscuous pan kinase scaffold.
Bioorg Med Chem Lett
; 25(13): 2679-85, 2015 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25980912
5.
Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.
Bioorg Med Chem Lett
; 25(22): 5155-62, 2015 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26475521
6.
A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3ß to phosphorylate cyclin D1 at Thr(286), not Thr(288).
Biochem J
; 457(1): 43-56, 2014 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24134204
7.
Discovery of novel imidazo[1,2-a]pyridines as inhibitors of the insulin-like growth factor-1 receptor tyrosine kinase.
Bioorg Med Chem Lett
; 21(16): 4698-701, 2011 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21775140
8.
PI3Kδ Forms Distinct Multiprotein Complexes at the TCR Signalosome in Naïve and Differentiated CD4+ T Cells.
Front Immunol
; 12: 631271, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33763075
9.
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Bioorg Med Chem Lett
; 18(6): 1799-803, 2008 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18313293
10.
A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Bioorg Med Chem Lett
; 18(2): 674-8, 2008 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18061446
11.
Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.
Oncotarget
; 9(30): 21444-21458, 2018 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29765551
12.
PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity.
J Immunother Cancer
; 6(1): 158, 2018 12 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-30587236
13.
The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
PLoS One
; 12(8): e0183048, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28806782
14.
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.
Sci Transl Med
; 9(394)2017 06 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28615361
15.
A Generic Platform for Cellular Screening Against Ubiquitin Ligases.
Sci Rep
; 6: 18940, 2016 Jan 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-26743172
16.
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.
Mol Cancer Ther
; 15(5): 877-89, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26839307
17.
Who would most benefit from improved integrated care? Implementing an analytical strategy in South Somerset.
Int J Integr Care
; 15: e001, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25674043
18.
Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.
J Med Chem
; 58(6): 2834-44, 2015 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-25738750
19.
Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.
Clin Cancer Res
; 20(1): 265-272, 2014 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24170544
20.
Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation.
J Med Chem
; 55(7): 3285-306, 2012 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-22417091